Johnson & Johnson looks expensive at 22x for its growth, even though its story is clean. Limited loss-of-exclusivity risk until the 2030s, a cleanup via spin-off and divestments, and a pipeline in IBS and cancer could deliver double-digit EPS growth before 2030, and Street estimates are probably too low. Still, Stryker at about 20x 2027 earnings, with high-single-digit organic growth and strong M&A skills, beats JNJ at 21x, which tends to overpay for growth like typical large pharma. x.com 

Johnson & Johnson's valuation does not make sense at a premium to Thermo Fisher and roughly flat to Danaher. @PythiaR, replying, calls J&J a clean story with limited patent-loss risk until the 2030s and a strong pipeline, but expensive at 22x, and prefers medtech such as Stryker. Pharma may simply have been easier to own than medtech given OBBB payer eligibility changes and hospital procedure volume risk, while life sciences has disappointed. x.com 

Johnson & Johnson is not the S&P 500 laggard its five-year sideways chart suggests once dividends and longer timelines are counted: over 20 years it trails the index by only the tiniest amount. That says something for a very low-beta stock with one of only two AAA credit ratings, alongside Microsoft. It is a strong anchor for when momentum and growth stocks get clobbered. x.com  x.com  x.com 

Debt-funded AI building is making tech stocks vulnerable to a 25-30% pullback as rates and energy prices rise. AI company borrowing reached $466B this year versus $101B a year earlier; weekly default-insurance trading on seven AI names rose from under $2B in July to over $9B in September. Keep cash for lower prices, though 30% earnings growth and a 19x market multiple argue this is not an AI bubble. x.com 

Alphabet's AI capex payback is being repriced, making its post-earnings decline more than a one-day mood swing. Guidance and cloud and AI margin commentary are the near-term tests. If growth continues but the multiple compresses, the risk is duration in mega-cap AI, not a collapse in technology growth. x.com 

Altria, Johnson & Johnson, Waste Management, TJX, Linde, Costco and Quest Diagnostics add defense to a portfolio, scoring highest among S&P 500 stocks on an antifragility screen of low volatility, strong free cash flow, minimal debt and stable earnings. All are also trending up this year, with momentum scores above 75; Altria scores 100 on antifragility and J&J 99. x.com 

Diversified cash flows in the billions make the AI-buildout basket more appealing than standalone model companies. Many members look reasonably priced and have longer records of delivering returns; Anthropic and OpenAI look much more like gambles at current valuations, though either could appeal at the right price. A possible equal-weight portfolio to revisit in five years includes Amazon, Alphabet, Microsoft, Meta, Oracle and SpaceX. x.com  x.com 

The Fed's September 16 quarter-point hike affects the high-moat portfolio differently from the simple picture of borrowers paying more. Bond-rating companies are having record quarters because the AI building boom keeps borrowing whatever rates do, while brokers that should win get only a small bump. The real damage falls on home loans and on the price investors will pay today for profits far in the future, which is where most of the portfolio sits. x.com 

Microsoft's balance sheet is stronger than many people think lately, as it is one of only two corporate AAA ratings left. The other belongs to Johnson & Johnson, and both are worth owning. x.com 

Financing risk makes AI-linked growth stocks unattractive to add here. Much of the money reaching suppliers such as Nvidia and Micron is financed, so harder funding would limit spending on chips, compute and memory. The buildout is not over, but stock prices could remain suppressed until it slows. A significant drawdown would make adding appealing; for many high-beta names with weak fundamentals and balance sheets, the highs look to be in. x.com